Results 1 to 10 of about 25,866 (210)

Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening [PDF]

Cell Death and Disease
The topoisomerase I inhibitor topotecan is an effective chemotherapeutic agent for retinoblastoma; however, treatment resistance remains a major clinical challenge, and its mechanisms remain elusive.
Jingyi Jiang, Zihua Jiang, Qian Luo, Xi Chen, Jiejie Zhuang, Jiaxin Chen, Qingqing Mu, Jin Qiu, Yan Li, Shuxia Chen, Ping Zhang, Keming Yu, Shuilian Chen, Guei-Sheung Liu, Jing Zhuang   +14 more
doaj   +2 more sources

High-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous seeding in retinoblastoma [PDF]

American Journal of Ophthalmology Case Reports
Purpose: To report on the use of intravitreal high-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous retinoblastoma, the toxicity of these injections, and the use of a 180-μG injection of intravitreal topotecan in humans. Observations:
David H. Abramson, Jasmine H. Francis
doaj   +2 more sources

In Vitro Stability and Preclinical Safety Evaluation of High-Dose Intravitreal Topotecan in Rabbits: Impact of Dose and Concentration [PDF]

Ophthalmology Science
Purpose: To assess the stability of concentrated solutions of topotecan and the ocular and systemic safety of administering repeated very high doses of intravitreal (IVi) topotecan in rabbits. Design: Experimental study.
María J. Del Sole, PhD, Pablo Nejamkin, PhD, Javier Opezzo, PhD, Debora Chan, PhD, Andrés Farall, PhD, Gabriela Lamas, MD, Fabiana Lubieniecki, MD, David H. Abramson, MD, Paula Schaiquevich, PhD   +8 more
doaj   +2 more sources

Suprachoroidal Injection of Topotecan for Retinoblastoma: A Preclinical Study [PDF]

Ophthalmology Science
Purpose: To assess whether levels of topotecan that are expected to be therapeutic against retinoblastoma tumors can be achieved within the retina and choroid by suprachoroidal injection (SCI) and to assess toxicity and safety in vivo.
Arun D. Singh, MD, Vishal Raval, MD, Sandeep Kumar, PhD, Anthony Daniels, MD   +3 more
doaj   +2 more sources

Molecular signatures of xenograft colorectal cancer in mice treated with topotecan: A mass spectrometry-based study [PDF]

Toxicology Reports
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide, yet it continues to have a low survival rate, largely due to the lack of effective treatments.
Yousra A. Hagyousif, Ruba A. Zenati, Nelson C. Soares, Hamza M. Al-Hroub, Farman Matloob Khan, Rizwan Qaisar, Rifat Hamoudi, Raafat El-Awady, Ahmad Y. Abuhelwa, Wafaa Ramadan, Waseem El-Huneidi, Eman Abu-Gharbieh, Karem H. Alzoubi, Yasser Bustanji, Mohammad H. Semreen   +14 more
doaj   +2 more sources

Real-Time Positron Emission Tomography Evaluation of Topotecan Brain Kinetics after Ultrasound-Mediated Blood–Brain Barrier Permeability

Pharmaceutics, 2021
Glioblastoma (GBM) is the most common primary adult brain malignancy with an extremely poor prognosis and a median survival of fewer than two years.
Andrei Molotkov, Patrick Carberry, Martin A. Dolan, Simon Joseph, Sidney Idumonyi, Shunichi Oya, John Castrillon, Elisa E. Konofagou, Mikhail Doubrovin, Glenn J. Lesser, Francesca Zanderigo, Akiva Mintz   +11 more
doaj   +1 more source

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. [PDF]

, 2016
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and ...
Brzezniak, Christina, Cabrales, Pedro, Caroen, Scott, Carter, Corey A, Degesys, Aiste, Oronsky, Bryan, Reid, Tony R, Scicinski, Jan   +7 more
core   +6 more sources

The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment. [PDF]

PLoS ONE, 2012
BACKGROUND: Topotecan produces DNA damage that induces autophagy in cancer cells. In this study, sensitising topotecan to colon cancer cells with different P53 status via modulation of autophagy was examined.
Dan-Dan Li, Ting Sun, Xiao-Qi Wu, Shu-Peng Chen, Rong Deng, Shan Jiang, Gong-Kan Feng, Jing-Xuan Pan, Xiao-Shi Zhang, Yi-Xin Zeng, Xiao-Feng Zhu   +10 more
doaj   +1 more source

Elucidation of Mechanisms of Topotecan-Induced Cell Death in Human Breast MCF-7 Cancer Cells by Gene Expression Analysis

Frontiers in Genetics, 2020
Topotecan is a clinically active anticancer agent for the management of various human tumors. While the principal mechanism of tumor cell killing by topotecan is due to its interactions with topoisomerase I and formation of DNA double-strand breaks ...
Birandra K. Sinha, Erik J. Tokar, Pierre R. Bushel   +2 more
doaj   +1 more source

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. [PDF]

, 2020
Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between the presence of anti-PD-1/PD-L1 therapeutic biomarkers and protein markers of potential chemotherapy response.
Arguello, David, Barkauskas, Donald A, Gatalica, Zoran, Kurzrock, Razelle, Nikanjam, Mina, Swensen, Jeff   +5 more
core   +2 more sources